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Recent developments in genetics/genomics of osteoarthritis (OA) are discussed to improve our under-
standing of OA pathophysiology. The discovery of a novel variant near the NCOA3 (nuclear receptor
coactivator 3) gene associated with hip OA and the regulation of GDF5 gene by four transcription factors
via the OA susceptibility locus rs143383 are among important ﬁndings in OA genetics. Several
microarray-based gene expression studies were published for different tissues of the joint. In OA
synovium elevation of collagens and cross-linking enzymes (COL1A1, COL5A1, PLOD2, LOX and TIMP1)
responsive to TGF-b was found as well as differential expression pattern between different areas of the
osteoarthritic synovial membrane. In OA peripheral blood the role of apoptotic genes was highlighted,
while whole genome expression proﬁling in OA subchondral bone and cartilage revealed common genes
in cartilage and bone to be involved in OA development. In epigenetics, several microRNAs (miRNAs)
were found to regulate genes’ expression in chondrocytes, among which miR-125, miR-127b miR-21,
miR-148a and their use as potential drug targets was highlighted. Future studies must focus on the
integration of genetics, genomics and epigenetics for the identiﬁcation of signaling pathways and reg-
ulatory networks responsible for OA development.
© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The goal of this review is to present highlights from the pub-
lished literature related to genetics, functional genomics and epi-
genetics of human osteoarthritis (OA). A summary of studies
published in PUBMED between April 2013 and May 2014, as well as
data presented during the 2014 OARSI meeting were selected by
the author and are included in the review.
OA is the most common degenerative joint disease and is pre-
dicted to be the single greatest cause of disability in the general
population by 20301. It has been estimated that 35% of persons
suffering from OA are active and therefore its negative impact on
work is liable to grow in view of the aging of the population and the
longer working lives in developed countries2. Despite its high
prevalence and substantial public health impact, disease etiology is
not fully understood. OA is a multifactorial disease with strong
genetic component and heritability estimates ranging from 40% to
65% depending on the joint site3e5. The identiﬁcation of genes
associated with OA will help reveal the underlying molecular
mechanisms and pathways and may lead to development of OA’
gene targeted therapies.ternational. Published by Elsevier LGenetics of OA
Numerous candidate gene association studies aiming to identify
disease susceptibility genes have been published in recent years,
although few positive results have been ﬁrmly replicated across
multiple populations. As with other complex diseases, Genome
Wide Association Studies (GWAS) have tested the association be-
tween thousands of single nucleotide polymorphisms (SNPs) in the
whole genome and OA. To date GWAS have identiﬁed 15 common
variants associated with knee or hip OA in European and Asian
populations that have surpassed or reached the genome wide sig-
niﬁcance level (P < 5  108)6,7. However, the identiﬁed individual
risk alleles have been found to exert only moderate to small effects
to the overall susceptibility to OA development7. Among them loci
on chromosome 13q34 near the MCF2L8 gene, on chromosome
7q229,10, rs143383 polymorphism in GDF5 gene11e13, DVWA, (HLA)
class II/III and BTNL2 genes14,15, 9q33 (ASTN2), 6q14 (FILIP1/SENP6),
12p11 (KLHDC5/PTHLH) and 12q23 (CHST11)16 were strongly asso-
ciated with hip or knee OA susceptibility. In addition, rs12982744
on 19q13 in DOT1L gene was associated with hip OA and cartilage
thickness17,18 and with lower height19,20. Growing evidence impli-
cates a functional polymorphism in the DIO2 gene as an OA risk
factor with a current meta-analysis P value for the association of
this gene with OA of 2.02  10521.td. All rights reserved.
A. Tsezou / Osteoarthritis and Cartilage 22 (2014) 2017e20242018Recently, a large GWAS meta-analysis from the TREAT-OA con-
sortium consisting of 11,277 cases with radiographic and symp-
tomatic hip OA and 67,473 controls, identiﬁed a novel variant
rs6094710 at 20q13 near the nuclear receptor coactivator 3 gene
(NCOA3) associated with hip OA6. The SNP is a G/A transition,
conferring to A allele carriers about 30% greater risk to develop hip
OA and this association reached genome wide signiﬁcance level
with P value 7.9  109 and odds ratio 1.28. Castano-Betancourt
et al. in a GWAS of 13,013 participants tested for associations be-
tween minimal joint space width (mJSW) genetic risk score and
mJSW/hip OA. They identiﬁed 5 novel loci, there of which, TGF-a,
RUNX-2, FGFR3, FGF3 were signiﬁcantly associated with cartilage
thickness and hip OA with P value <104, suggesting that the
identiﬁed loci for mJAWmay be used to risk-stratify individuals for
hip OA22.
In addition, several meta-analyses of candidate gene association
studies have been conductedwith positive and negative association
for OA susceptibility. In a recent meta-analysis several BMD-iden-
tiﬁed SNPs were nominally associated with knee OA risk. The
strongest signal mapped to 12q3, which contains a gene coding for
SP 7 with odds ratio 1.22 and a P value of 9  104. Additional loci
map to 7p14.1 (TXNDC3), 11q13.2 (LRP5) and 11p14.1 (LIN7C). For all
four loci the allele associated with higher BMDwas associated with
higher odds of OA supporting the hypothesis that BMD may be a
risk factor contributing to OA development23.
An assessment of OA candidate gene approach in a meta-
analysis of 9 GWAS in Europeans including 5,636 knee OA pa-
tients and 16,972 controls and 4,349 hip OA and 17,836 controls
found that SNPs at only two genes, COL11A1 and VEGF, of the 199
analyzed OA candidate genes were associated with hip OA24.
COL11A1 showed two independent associations, rs4907986 with
odds ratio 1.12, 95 % CI 1.06e1.17 and a P value of 1.29  105 and
rs1241164 with OR 0.82, CI 0.74e0.89 and a P value of 1.47  105,
while VEGF was associated in a male-speciﬁc analysis (rs833058,
odds ratio 0.85, CI 0.79e0.91 and a P value of 1.35  105), pointing
to the lack of reproducibility of OA candidate gene studies24. No
association was found between knee and hip OA and the D13, D14
and D15 repeats of asporin gene (ASPN) in Caucasian and Asian
populations in a meta-analysis including 4,417 OA patients and
3,403 controls25 and between VDR BsmI, TaqI and ApaI poly-
morphisms and OA in a meta-analysis including 1,626 knee, hip,
hand and lumbar spine OA cases and 2,024 controls26,27. Another
meta-analysis including 5,409 knee OA patients, 4,355 hip OA pa-
tients and 5,362 healthy controls showed there is no direct impli-
cation of the FTO gene with OA susceptibility and that the effect of
the FTO variant rs8044769 on OA is solely due to its effect on BMI28.
Furthermore, in the period covered in this review, several OA
candidate gene association studies have been published. However,
only studies with large numbers of participants and/or functional
studies will be mentioned. The polymorphism rs11564299 in the N-
cadherin (CDH2) promoter region was associated with OA risk in
312 OA patients and 259 controls, with odds ratio 1.14, 95% CI
0.49e2.62 and a P value of 1.5  103, with carriers of the minor
allele of rs11564299 displaying increased N-cadherin levels in sy-
novial ﬂuid29. In silico analysis showed that the minor allele
generated a novel transcription factor binding site and hnRNPKwas
found to be involved in the regulation of elevated N-cadherin
expression in OA patients carrying theminor allele of rs1156429929.
The functional exon 3 deleted growth hormone receptor gene
polymorphism (d3-GHR) was associated with symptomatic hip OA
independently of age and BMI in a combined analysis consisting of
2,175 female cases and 2,623 controls with pooled odds ratio 1.17,
95% CI 1.04e1.32 and a P value of 8  10330. Vidal-Bralo et al.
identiﬁed a new functional microsatellite in macrophage migration
inhibitory factor (MIF) gene associated with hip OA in a case-control study including 1,775 knee OA patients, 1,782 hip OA pa-
tients and 1,878 controls from three European cohorts with P of the
ManteleHaenszel analysis 1.8  102 in women and 2.9  102 in
men31. For all above candidate gene association studies, replication
studies in different ethnic populations, as well as functional studies
for the identiﬁcation of the mechanisms that confer increased OA
risk are needed.
Until now, all identiﬁed OA-associated variants explain only a
small fraction of less than 10% of the genetic component. Large-
scale studies with whole-genome sequencing focusing on vari-
ants with lowminor allele frequency (MAF 1e5%) and rare variants
(MAF <1%) have already starting to emerge7. Complete sequence of
large OA cohorts will undoubtedly result in novel DNA-variants
contributing to disease susceptibility. A recent GWAS identiﬁed
through whole-genome sequencing of 2,230 individuals, two
genome-wide signiﬁcant loci, rs4238326(C/T) with odds ratio1.44,
95% CI 1.29e1.60 and a P value of 8.6  1011 and rs3204689(C/G)
with odds ratio 1.46, CI 1.31e1.63 and a P value of 1.1  1011 at
15q22 in the ALDH1A2 gene and a rare variant at 1p31 with odds
ratio 47.7 and a P value of 1.53  10932. The variants within the
ALDH1A2 gene were conﬁrmed in replication sets from the
Netherlands and the UK yielding an overall association with odds
ratio 1.46 and a P value of 1.1  101132. Allelic imbalance analysis
for rs3204689 showed that the transcript with the risk-conferring C
allele was expressed at a lower level in cartilage and adipose tissue
compared to the non-risk allele, suggesting that ALDH1A2mediates
the effect of the OA risk variants in the associated locus32. It is
interesting that carriers of the rare variant at 1p31 belonged to an
Icelandic family, in several members of which, the risk allele
segregated with hand and generalized OA32. An exome-sequencing
study conducted in 199 hip OA cases and 1,337 controls and in a
group of hip OA and mJSW candidate genes (ASTN2, DIO2, DOT1L,
FGFR3, FILIP1, GLT8D1, GNL3, MCF2L, NCOA3, PIK3R1, PTHLH, RUNX2,
SENP6, TGF-a) identiﬁed 761 variants in these genes associatedwith
hip OA and mJSW33. The strongest signal for mJSW was a rare
variant in the FGF3 gene with a P value of 8.6  105, which how-
ever was not associated to the GWAS signal identiﬁed before by the
same group22. FGFR3 has previously been shown to be involved in
endochondral bone formation and mutations in FGFR3 result in
achondroplasia33. Functional assessment of the identiﬁed variant is
awaited.
Functional studies in OA loci
So far there are limited functional studies that provide possible
mechanisms by which genetic variation at OA susceptibility genes
confer increased OA risk. Genetic variation at the type II deiodinase
(D2) gene (DIO2) has been identiﬁed as OA risk factor. Bos et al.
showed that in OA cartilage, ligaments and subchondral bone there
is differential allelic expression of DIO2 mRNA, with the OA-
associated 'C' allele of rs225014 in the DIO2 gene being more
abundant in heterozygous carriers (1.3-fold higher presence) than
the wild type allele, suggesting that genetic variation at DIO2might
confer to OA risk34. The same group recently identiﬁed a possible
molecular mechanism of DIO2 susceptibility in symptomatic OA35.
It was shown that OA-related changes in methylation at CpG-2031,
upstream of DIO2, caused signiﬁcant upregulation of its expression,
with b 4.96 and a P value of 1.6  103, despite the conventional
inverse relation between CpG methylation and gene expression,
and this effect appeared to be driven by the DIO2 rs225014 risk
allele, with b 5.58 and a P value of 6  10435. Using an in vitro
chondrogenesis model with genetically modiﬁed hBMSC it was
shown that up-regulation of DIO2 induced EPAS1 and RUNX2
mediated up-regulation of cartilage degrading enzymes (MMP-13
and ADAMTS5) and markers of mineralization (ALPL)35. However, as
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previously assessed allelic imbalance34 was not demonstrated, it
was suggested that SNP rs225014 probably affects three-
dimensional chromatin conformations, underlying the relation
between the rs225014 tagged allelic imbalance and methylation-
dependent up-regulation of DIO2 among rs225014 risk allele car-
riers35. To conclude on the functional role of SNP rs225014 in DIO2
gene in OA susceptibility, further studies are awaited. In addition,
the recently identiﬁed DOT1L gene was suggested to play a role in
chondrogenic bone development via regulation of Wnt-signaling17.
The GDF5 SNP rs143383 is the best-understood OA locus. It has
been shown to exert its effect via regulation of transcription of the
gene in which the T susceptibility allele leads to lower expression
levels11. Recently, Sydall et al. identiﬁed four trans-acting factors
Sp1, Sp3, P15, and DEAF-1 that bind differentially to the alleles of
rs143383 and which contribute to the differential allelic expression
that is mediated by this OA susceptibility locus. Knockdown and
over expression of these factors demonstrated that Sp1, Sp3, and
DEAF-1 are repressors of GDF5 expression36. The authors proposed
a binding model of the four trans-acting factors to rs143383, ac-
cording to which DEAF-1, Sp1 and Sp3 are forming a repressive
complex that forms directly over rs143383 and are differentially
modulating the expression of the C and T alleles. P15 may be
interacting with this complex and serving as a linker between Sp1
and the general transcription machinery36. The identiﬁed tran-
scriptional factors could serve as potential therapeutic targets as
their depletion might restore GDF5 expression's levels in patients
with the OA susceptibility T allele36.
Furthermore, the expression level of the latest identiﬁed variant
rs6094719 in NCOA3 gene was found to be signiﬁcantly lower in OA
cartilage compared to preserved cartilage (macroscopically normal
but isolated from the same joint) with a P value of 6.4  1036. The
molecular mechanism by which NCOA3 contributes to OA is not
clear. NCOA3 is involved in the co-activation of different receptors,
as steroids, retinoids, thyroid hormone, vitamin D3 and prosta-
noids, several of which are involved in skeletal metabolism and
OA6. NCOA3 knockout mice showed growth retardation and
reduced adult body size, while female knockout mice exhibited
abnormal development and function of their reproductive system
and lower eostrogen levels comparedwith thewild type, indicating
a possible role of NCOA3 in steroid regulation37. Other possible
mechanisms by which NCOA3 might be involved in cartilage ho-
meostasis is through transcriptional regulation in mechano-
transduction or through regulation of the target tissue responses to
thyroid hormone (T3)38,39.
Rushton et al. in the 2014 OARSI meeting showed reduced
expression of NCOA3 in individuals carrying a copy of the OA
associated A-allele in fat pad and synovial membrane from OA
patients40. Furthermore, NCOA3 was shown to be up-regulated in
hip OA cartilage relative to the control non-OA cartilage OA40, in
contrast to the observed downregulation by Evangelou et al.6. The
discrepancy in NCOA3 gene expression between the two studies
could be attributed to the different source of control cartilage, as
Evangelou et al. used as control macroscopically normal cartilage
from an OA joint (preserved cartilage) and not non-OA hip cartilage.
Previous studies have demonstrated that cartilage from macro-
scopically and histologically intact regions from an OA joint (pre-
served cartilage) exhibits differential gene (leptin (LEP)) expression
levels than normal (non-OA) cartilage41.
Microarray-based gene expression studies
Several studies have analyzed the expression pattern of different
genes, usingmicroarray technology to determine their involvement
in OA pathogenesis. Catabolic enzymes such as ADAMTS5, ADAMTS1and MMP1 were found increased in knee OA and decreased in hip
OA strengthening the idea that OA is characterized by joint speci-
ﬁcity42. In addition, osteophytic cartilage showed increased
expression of genes involved in terminal chondrocytes differenti-
ation and endochondral ossiﬁcation such as BGLAP, BMP8B, COL1A2,
SOST, RUNX2, compared to articular cartilage, which showed
increased levels of antagonists and inhibitors of the BMP- andWnt-
signaling pathways as GREM1, FRZB, WISP343.
Recently, incorporation of microarray-based studies along with
network analysis has led to advancement in our understanding of
pathways involved in OA pathogenesis. Several microarray-based
gene expression-proﬁling studies have been performed in
different tissues of the OA joint. In the period covered in this re-
view, gene expression analysis in two different regions of OA sy-
novial membrane of the same patient, inﬂamed and normal,
revealed differentially expressed genes belonging to pathways
related to inﬂammation, cartilage metabolism, Wnt signaling and
angiogenesis44. In the inﬂammatory network, TREM1 and S100A9
were strongly up-regulated,MMP-3 and -9, cathepsin H and S were
up-regulated in the cartilage catabolism pathway,Wnt-5A and LRP5
were up-regulated in the Wnt signaling and STC1 coding for a
protein involved in angiogenesis was themost up-regulated gene in
the inﬂammatory region of the synovial membrane44. The alarmin
S100A9 might a be a gene of interest, as it was shown that it
stimulates osteophyte formation in experimental OA and predicts
osteophyte progression in early OA patients45, pointing towards the
potential use of S100A9 as a biomarker predictive of joint
destruction. Another microarray-based gene expression analysis in
end-stage OA synovium revealed increased expression of trans-
forming growth factor-beta responsive genes in OA-related ﬁbrosis,
such as COL1A1 (7-fold, P < 103) and COL5A1 (4-fold,
P < 3.6  102) and genes encoding for collagen cross-linking en-
zymes, such as PLOD2 (25)-fold, P < 103 and LOX (3-fold, P < 103),
speculating that PLOD2might be an attractive and promising target
to interfere in OA-related synovial ﬁbrosis46.
In the ﬁrst whole-genome expression proﬁling study of sub-
chondral bone, Chou et al. identiﬁed 972 differentially expressed
genes in chondrocytes from 20 OA and 5 non-OA knee lateral tibial
and medial tibial plateaus (>2-fold, P < 5  102)47. Pathway
analysis with the most up-regulated and down-regulated genes
identiﬁed a novel signaling network in OA characterized by up
regulation of bone mineralization or collagen-associated genes,
such as COL3A1, BMP1, BMP7, POSTN, WISP1, HTRA1, SOST, ITGA11,
angiogenesis genes as ANGPTL1 and by down-regulation of genes
associated with cellular metabolism, proliferation or differentia-
tion, such as NMB, LEP, CHRDL2, GRB14, CIDEC, CIDEA, BTG2, PLAC8,
and PRDM16. A novel ﬁnding was the implication of periostin
(POSTN) and leptin (LEP) in bone remodeling by osteoblasts47.
In addition, gene expression proﬁling in peripheral blood of
non-OA and patients with familial OA revealed 694 unique genes
differentially expressed between cases and controls, including 86
genes expressed with at least 1.5-fold difference48. ATF4, GPR18 and
H3F3B were among the top identiﬁed genes with a P value of
4.5  108. It is interesting that in OA patients, apoptosis pathway
genes were found signiﬁcantly enriched including CASP3 and FAS-
associated death domain (FADD). However, the identiﬁed genes
need to be validated in a population-based setting before being
considered as early OA markers48.
DNA methylation and OA
DNA methylation is at the moment the most well studied
epigenetic mechanism in OA49. Methylation proﬁling of bone has
revealed differentially methylated regions between osteoporosis
and OA, including regions that were enriched in genes associated
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several genes have been reported with altered DNA methylation
patters in OA. Reduced methylation of speciﬁc CpG sites was
associated with increased MMP-3, 9, 13 and ADAMTS-4 expression
levels in end-stage OA chondrocytes51e53, while the DNA methyl-
ation status of MMP-13 and iNOS was shown to affect their tran-
scriptional regulation in OA through changes of the binding afﬁnity
of transcriptional factors54e56. In MMP-13 promoter, the sites
at 104 and 110 bp site have been demonstrated as methylation
modulated CREB and HIF-2a binding sites, respectively54,56. The
methylation of CpG sites at 5853 and 5842 in an enhancer of
iNOS repressed the binding of p65 subunit of NF-kB, suggesting the
epigenetic regulation of iNOS in OA55. Moreover, hypermethylation
of SOD and SOX-9 promoter has been associated with decreased
gene expression in OA cartilage in an animal model of OA57.
Recently, a genome-wide DNA methylation analysis of articular
chondrocytes in 25 OA patients and 20 healthy controls showed
different methylation status between patients and controls58.
Genome-wide expression analysis in the same cohort, revealed the
existence of a tight cluster of OA patients with differential gene
expression characterized with increased inﬂammatory response.
The most consistent genes were validated in an independent OA
cohort, identifying thus novel genes as potential OA markers58.
Taylor et al. identiﬁed a new epigenetic mark, 5 hydrox-
ymethylcytosine (5 hmC) globally increased in knee OA chon-
drocytes compared to normal. 5 hmC is an intermediate in DNA
demethylation generated from the conversion of 5 mC to 5 hmC
through TET1,2,3 enzymes59,60. The increase in 5 hmC (5e6-fold)
was concomitant with loss of TET1 in OA chondrocytes. In addition,
the enrichment of 5 hmC at speciﬁc CpG sites in the MMP-1 and
MMP-3 promoters correlated with increased MMPs expression in
OA chondrocytes. This sitewas proximal to the CpG site undergoing
signiﬁcant DNA demethylation in OA chondrocytes (635 bp)
suggesting a role of 5 hmC in active DNA demethylation60. It is
important, however, to analyze other CpG sites in MMP genes,
especially in exons, to clarify the role of 5 hmC in regulating MMPs
gene expression in OA. In a genome wide DNA methylation
proﬁling of knee and hip osteoarthritic and preserved (macro-
scopically normal cartilage from OA joint) articular cartilage den
Hollander et al. showed that methylation of CpG dinucleotides
differs substantially between hips and knees61. Also, the identiﬁed
methylation changes at a multitude of CpG dinucleotides were
associated with gene expression in articular cartilage of novel
genes, such as IGFBP7, LOXL3,MALL, BFSP1 and SLC7A5, as well as OA
associated genes, such as CRLF1, COL6A3, CD44, CILP and TGFBI61. In
another genome-wide methylation study in knee and hip OA
cartilage, Rushton et al. found differential methylation proﬁle be-
tween OA and non-OA cartilage and also between hip and knee
OA62. In addition, two groups of expression patterns were identiﬁed
in knee OA cartilage and these two groups were also present in hip
OA cartilage, conﬁrming the differences in methylation proﬁle be-
tween knee and hip OA62. Differences in whole genome methyl-
ation proﬁling between knee and hip OA cartilage were a common
ﬁnding in both of the above-mentioned genome-wide methylation
proﬁling studies, pointing to the contrasting nature of OA pro-
gression between the two joints.MicroRNAs and OA
To date, almost all studies into the role of non-coding RNAs
(ncRNAs) in cartilage biology and OA have concentrated on
microRNAs (miRNAs). MicroRNAs are small, 18e24 nucleotides in
length, single-stranded noncoding RNA molecules, that negatively
regulate the expression of target genes in a post-transcriptionalmanner by binding to speciﬁc sequences within target messenger
RNAs (mRNAs)63.
Previous large-scale microarray miRNA analysis identiﬁed nine
up regulated microRNAs, miR-16, miR-22, miR-23b, miR-30b, miR-
103, miR-223, miR-377, miR-483 and miR-509 and seven down-
regulated microRNAs, miR-25, miR-26a, miR-29a, miR-140, miR-
210, miR-337 and miR-373 in OA compared to normal cartilage64.
Functional experiments identiﬁed miR-22 to be implicated in
obesity and inﬂammation64, miR-9 in MMP-13 regulation and miR-
9, miR-98 andmiR-146 in the control of tumor necrosis factor (TNF)
expression, suggesting that these miRNAs may have a protective
role in OA64,65. Another microarray based microRNA study revealed
that miR-483-5p was upregulated in OA chondrocytes, while miR-
149, miR-582-3p, miR-1227, miR-634, miR-576-5p, and miR-641
were up-regulated in normal chondrocytes. These miRNAs were
predicted to function in articular cartilage via the TGF, Wnt, and Erb
signaling66. MicroRNA-140, is a critical miRNA in OA as it is spe-
ciﬁcally expressed by chondrocytes and plays important role in
chondrogenesis and cartilage development67,68. Knockout or over-
expression of miR-140 in vivo was shown to have profound effects
on the development of OA and it was shown to directly mediate
MMP-13 expression in vitro69,70. Other studies identiﬁed miR-27a
and 27b to regulate the expression levels of MMP-13 in OA chon-
drocytes, in an indirect or direct manner, respectively71,72, whereas
miR-146a has also been suggested to function as a negative feed-
back regulator of MMP-13. miR-146a is strongly expressed in
cartilage with mild OA but its expression gradually decreases with
advancement of disease and is inversely correlated with the
expression of MMP-13 in OA cartilage73,74. Recently, Wang et al.
showed that HDAC inhibitors increase miR-146a expression and
enhance negative regulation of interleukin-1b signaling in OA
ﬁbroblast-like synoviocytes75. However, due to toxicity and off-
target side effects of HDAC inhibitors, their use in OA may be
problematic.
Recent studies in knee OA cartilage and healthy articular
cartilage showed that miR-125b is down regulated in OA cartilage
and that it directly regulates ADAMTS-4 through IL-1b activa-
tion76. In addition, Park et al. showed that miR-558 is down
regulated in OA chondrocytes and that it directly targets COX-2
and regulates IL-1b stimulated catabolic effects in chon-
drocytes77. Another microRNA, miR-127-5p was also down regu-
lated in knee OA cartilage compared to normal and the IL-1b-
induced up regulation of MMP-13 expression was correlated with
miR-127-5p down regulation in chondrocytes. MicroRNA-127-5p
suppressed IL-1b-induced MMP-13 production, while anti-miR-
127-5p signiﬁcantly increased MMP-13 production, suggesting
that miR-127-5p may be an important regulator of MMP-13
expression in human chondrocytes78. In addition, miR-148a was
found down-regulated in knee OA chondrocytes compared to
normal79. Its overexpression decreased COL10A1, MMP-13 and
ADAMTS5 and increased COL2A1 expression. The matrix deposited
by miR-148a overexpressing chondrocytes contained more pro-
teoglycans and collagen, in particular collagen type II, pointing to
its role as a potential disease-modifying compound in OA79.
Furthermore, endogenous miR-21 was found up-regulated in knee
OA cartilage compared to control and overexpression/inhibition
experiments showed that miR-21 suppresses the maturation of
CH8 cells and chondrogenesis process80. In addition miR-21
overexpression resulted in signiﬁcant increase in MMP1, MMP2,
MMP3, MMP9 expression, while miR-21 inhibition decreased their
expression. Bioinformatic analysis predicted miR-21 to be a target
of GDF-5 and a luciferase activity assay showed that GDF-5 is
directly targeted by miR-21, which induces GDF-5 mRNA decay,
suggesting that it might be a potential therapeutic target80.
Swingler et al. using chocndrocytes from an animal model of OA as
Table I
MicroRNAs in OA
miRNA Tissue Regulation in OA Biological function/pathways involved Target genes Reference
mir-16, mir-23b, mir-30b, mir-103,
mir-223, mir-377, mir-483, mir-509
Cartilage Up-regulated 64
miR-25, miR-26a, miR-29a, miR-210,
miR-337, miR-373
Cartilage Down-regulated 64
miR-22 Cartilage Up-regulated Inﬂammatory response, aging PPARa, BMP7 64
miR-140 Cartilage Down-regulated Cartilage homeostasis ADAMST5, Aggrecan,
MMP-13, IGFBP5
64,72,73
miR-149 Chondrocytes Down-regulated TGF-b, Wnt, Erb and mTOR signaling 66
mir-27a Chondrocytes Down-regulated Cartilage homeostasis MMP-13 72
mir-27b Chondrocytes Down-regulated Cartilage homeostasis MMP-13 71
mir-146a Cartilage/Synoviocytes Up-regulated Chondrocyte apoptosis VEGF, SMAD4 73e75
miR-146 Cartilage Down-regulated Inﬂammatory response (NF-kB pathway) TRAF6, IRAK1 65
miR-9 Cartilage/Bone Up-regulated Inﬂammatory process MMP-13 65
miR-98 Cartilage/Bone Up-regulated Inﬂammatory process TNF-a 65
miR-483-5p Cartilage Up-regulated TGF-b, Wnt, Erb and mTOR signaling 66
miR-576-5p, mir-634, mir-641, mir-1227 Cartilage Down-regulated TGF-b, Wnt, Erb and mTOR signaling 66
miR-125b Cartilage Down-regulated Cartilage homeostasis ADAMTS-4 76
miR-127-5p Cartilage Down-regulated Cartilage homeostasis MMP-13 78
miR-558 Cartilage Down-regulated Cartilage homeostasis COX-2 77
miR-21 Chondrocytes Up-regulated Inhibition of chondrocyte proliferation GDF-5 80
let-7e Serum Down-regulated 82
miR-148a Cartilage Down-regulated Cartilage homeostasis COL10A1, MMP-13,
ADAMTS5
79
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family as microRNAs which act early in OA development, are
regulated by important factors in OA, as TGF-b, SOX-9 and have
functional impact on relevant pathways, as NF-kB, canonical Wnt,
Smad81. In addition, novel genes, as ADAMTS5, ADAMTS6,
ADAMTS14, ADAMTS17, ADAMTS19, FZD3, DVL3, FRAT2, CK2A2 were
validated as direct targets of microRNA 29 family. Identiﬁcation of
pathways through which miR-29 family regulates development
and OA progression is awaited81. In a recent study, Beyer et al.
identiﬁed in a population-based cohort including 816 Caucasians
with OA necessitating arthroplasty, differentially expressed circu-
lating microRNAs82. Among the identiﬁed microRNAs, three
microRNAs, let-7e, miR-454 and miR-885-5p were identiﬁed as
predictors for severe knee or hip OA. After the application of very
stringent criteria for arthroplasty and statistical analysis, let-7e
emerged as a potential predictor for severe knee or hip OA
arthroplasty, as its association to OA was independent of age, sex
and BMI with 95% CI 0.61e0.97 and a P value of 2.8  10282. To
assess let-7e value, its validation in different cohorts and different
applications is awaited. Table I shows the microRNAs that have
been identiﬁed to have a role in OA, the biological processes they
are involved and their targets.
As more and more microRNAs are revealed to play roles during
chondrogenesis, cartilage ho-meostasis and OA pathogenesis, the
identiﬁcation of microRNAs key targets that functionally impact OA
pathogenesis and disease progression and the mechanisms of
microRNAs regulation are necessary.
Summary
Only a few loci have been associated with OA at genome-wide
signiﬁcance levels despite extensive efforts and even these sig-
nals have a small effect size. As a proportion of the genetic sus-
ceptibility to OA is due to low frequency and rare variants, next-
generation sequencing in large populations is expected to lead to
the detection of rare variant associations with OA risk. To obtain a
better understanding of OA, integration of functional genomics,
microarray-based gene expression studies and network-based
analysis, along with epigenetics is essential for the identiﬁcation
of signaling pathways regulated during disease development.Author contribution
Aspasia Tsezou searched the literature, summarized the results
and wrote the manuscript.Role of the funding source
No funding was obtained for this paper.Conﬂict of interests
The author has no competing interests.Acknowledgments
I apologize to all those, whose work was not cited.References
1. Thomas E, Peat G, Croft P. Deﬁning and mapping the person
with osteoarthritis for population studies and public health.
Rheumatology (Oxford) 2014;53:338e45.
2. Taieb C, Bruel P, Auges M. Knee arthritis: a conﬁrmed burden.
Osteoarthritis and Cartilage 2014;22:S224e5.
3. Jordan JM, Kraus VB, Hochberg MC. Genetics of osteoarthritis.
Curr Rheumatol Rep 2004;6:7e13.
4. Kraus VB, Jordan JM, Doherty M, Wilson AG, Moskowitz R,
Hochberg M, et al. The genetics of generalized osteoarthritis
(GOGO) study: study design and evaluation of osteoarthritis
phenotypes. Osteoarthritis Cartilage 2007;15:120e7.
5. Spector TD, Cicuttini F, Baker J, Loughlin J, Hart D. Genetic
inﬂuences on osteoarthritis in women: a twin study. BMJ
1996;312:940e3.
6. Evangelou E, Kerkhof HJ, Styrkarsdottir U, Ntzani EE, Bos SD,
Esko T, et al. A meta-analysis of genome-wide association
studies identiﬁes novel variants associated with osteoarthritis
of the hip. Ann Rheum Dis 2013, http://dx.doi.org/10.1136/
annrheumdis-2012-203114.
7. Panoutsopoulou K, Zeggini E. Advances in osteoarthritis ge-
netics. J Med Genet 2013;50:715e24.
A. Tsezou / Osteoarthritis and Cartilage 22 (2014) 2017e202420228. Day-Williams AG, Southam L, Panoutsopoulou K, Rayner NW,
Esko T, Estrada K, et al. A variant in MCF2L is associated with
osteoarthritis. Am J Hum Genet 2011;89:446e50.
9. Evangelou E, Valdes AM, Kerkhof HJ, Styrkarsdottir U, Zhu Y,
Meulenbelt I, et al. Meta-analysis of genome-wide association
studies conﬁrms a susceptibility locus for knee osteoarthritis
on chromosome 7q22. Ann Rheum Dis 2011;70:349e55.
10. Kerkhof HJ, Lories RJ, Meulenbelt I, Jonsdottir I, Valdes AM,
Arp P, et al. A genome-wide association study identiﬁes an
osteoarthritis susceptibility locus on chromosome 7q22.
Arthritis Rheum 2010;62:499e510.
11. Miyamoto Y, Mabuchi A, Shi D, Kubo T, Takatori Y, Saito S, et al.
A functional polymorphism in the 5' UTR of GDF5 is associated
with susceptibility to osteoarthritis. Nat Genet 2007;39:
529e33.
12. Valdes AM, Evangelou E, Kerkhof HJ, Tamm A, Doherty SA,
Kisand K, et al. The GDF5 rs143383 polymorphism is associ-
ated with osteoarthritis of the knee with genome-wide sta-
tistical signiﬁcance. Ann Rheum Dis 2011;70:873e5.
13. Sanna S, Jackson AU, Nagaraja R, Willer CJ, Chen WM,
Bonnycastle LL, et al. Common variants in the GDF5-UQCC
region are associated with variation in human height. Nat
Genet 2008;40:198e203.
14. Miyamoto Y, Shi D, Nakajima M, Ozaki K, Sudo A, Kotani A,
et al. Common variants in DVWA on chromosome 3p24.3 are
associated with susceptibility to knee osteoarthritis. Nat Genet
2008;40:994e8.
15. Nakajima M, Takahashi A, Kou I, Rodriguez-Fontenla C,
Gomez-Reino JJ, Furuichi T, et al. New sequence variants in
HLA class II/III region associated with susceptibility to knee
osteoarthritis identiﬁed by genome-wide association study.
PLoS One 2010;5:e9723.
16. arcOGEN Consortium, arcOGEN Collaborators, Zeggini E,
Panoutsopoulou K, Southam L, Rayner NW, Day-Williams AG,
Lopes MC, et al. Identiﬁcation of new susceptibility loci for
osteoarthritis (arcOGEN): a genome-wide association study.
Lancet 2012;380:815e23.
17. Casta~no Betancourt MC, Cailotto F, Kerkhof HJ, Cornelis FM,
Doherty SA, Hart DJ, et al. Genome-wide association and
functional studies identify the DOT1L gene to be involved in
cartilage thickness and hip osteoarthritis. Proc Natl Acad Sci
USA 2012;109:8218e23.
18. Evangelou E, Valdes AM, Castano-Betancourt MC, Doherty M,
Doherty S, Esko T, et al. The DOT1L rs12982744 polymorphism
is associated with osteoarthritis of the hip with genome-wide
statistical signiﬁcance in males. Ann Rheum Dis 2013;72:
1264e5.
19. Lango Allen H, Estrada K, Lettre G, Berndt SI, Weedon MN,
Rivadeneira F, et al. Hundreds of variants clustered in genomic
loci and biological pathways affect human height. Nature
2010;467:832e8.
20. Sovio U, Bennett AJ, Millwood IY, Molitor J, O'Reilly PF,
Timpson NJ, et al. Genetic determinants of height growth
assessed longitudinally from infancy to adulthood in the
northern Finland birth cohort 1966. PLoS Genet 2009;5:
e1000409.
21. Meulenbelt I, Min JL, Bos S, Riyazi N, Houwing-Duistermaat JJ,
van der Wijk HJ, et al. Identiﬁcation of DIO2 as a new sus-
ceptibility locus for symptomatic osteoarthritis. Hum Mol
Genet 2008;17:1867e75.
22. Castano Betancourt M, Evans D, Liu Y, Yau M, Uitterlinden A,
Evangelou V, et al. Novel variants for cartilage thickness and
hip osteoarthritis: revealing genes implicated in cartilage and
bone development. Osteoarthritis and Cartilage 2014;22:S41.23. Yerges-Armstrong LM, Yau MS, Liu Y, Krishnan S, Renner JB,
Eaton CB, et al. Association analysis of BMD-associated SNPs
with knee osteoarthritis. J Bone Min Res 2014;29:1373e9.
24. Rodriguez-Fontenla C, Calaza M, Evangelou E, Valdes AM,
Arden N, Blanco FJ, et al. Assessment of osteoarthritis candi-
date genes in a meta-analysis of nine genome-wide associa-
tion studies. Arthritis Rheumatol 2014;66:940e9.
25. Song GG, Kim JH, Lee YH. A meta-analysis of the relationship
between aspartic acid (D)-repeat polymorphisms in asporin
and osteoarthritis susceptibility. Rheumatol Int 2014;34:
785e92.
26. Liu H, He H, Li S, Yang L, Wang P, Liu C, et al. Vitamin D re-
ceptor gene polymorphisms and risk of osteoarthritis: a meta-
analysis. Exp Biol Med (Maywood) 2014;239:559e67.
27. Zhu ZH, Jin XZ, Zhang W, Chen M, Ye DQ, Zhai Y, et al. Asso-
ciations between vitamin D receptor gene polymorphisms and
osteoarthritis: an updated meta-analysis. Rheumatology (Ox-
ford) 2014;53:998e1008.
28. Panoutsopoulou K, Metrustry S, Doherty SA, Laslett LL,
Maciewicz RA, Hart DJ, et al. The effect of FTO variation on
increased osteoarthritis risk is mediated through body mass
index: a mendelian randomisation study. Ann Rheum Dis
2013; Feb 4, http://dx.doi.org/10.1136/annrheumdis-2013-
203772. [Epub ahead of print].
29. Ruedel A, Stark K, Kaufmann S, Bauer R, Reinders J, Rovensky J,
et al. N-cadherin promoter polymorphisms and risk of osteo-
arthritis. FASEB J 2014;28:683e91.
30. Claessen KM, Kloppenburg M, Kroon HM, Bijsterbosch J,
Pereira AM, Romijn JA, et al. Relationship between the func-
tional exon 3 deleted growth hormone receptor poly-
morphism and symptomatic osteoarthritis in women. Ann
Rheum Dis 2014;73:433e6.
31. Vidal-Bralo L, Rodriguez-Fontela C, Calaza M, Oreiro N,
Blanco FJ, Carr A, et al. New functional microsatellite associ-
ated with osteoarthritis susceptibility. Osteoarthritis and
Cartilage 2014;22:S232e3.
32. Styrkarsdottir U, Thorleifsson G, Helgadottir HT, Bomer N,
Metrustry S, Bierma-Zeinstra S, et al. Severe osteoarthritis of
the hand associates with common variants within the
ALDH1A2 gene and with rare variants at 1p31. Nat Genet
2014;46:498e502.
33. Boer CG, Jv Rooij, Peters M, Kraaij R, Jhamai M, Arp P, et al.
Discovery and analysis of rare coding variants for hipOA by
exome-sequencing. Osteoarthritis and Cartilage 2014;22:
S226e7.
34. Bos SD, Bovee JV, Duijnisveld BJ, Raine EV, van Dalen WJ,
Ramos YF, et al. Increased type II deiodinase protein in OA-
affected cartilage and allelic imbalance of OA risk poly-
morphism rs225014 at DIO2 in human OA joint tissues. Ann
Rheum Dis 2012;71:1254e8.
35. Bomer N, den Hollander W, Ramos YF, Bos SD, van der
Breggen R, Lakenberg N, et al. Underlying molecular mecha-
nisms of DIO2 susceptibility in symptomatic osteoarthritis.
Ann Rheum Dis 2014; Apr 2, http://dx.doi.org/10.1136/annr-
heumdis-2013-204739. [Epub ahead of print].
36. Syddall CM, Reynard LN, Young DA, Loughlin J. The identiﬁ-
cation of trans-acting factors that regulate the expression of
GDF5 via the osteoarthritis susceptibility SNP rs143383. PLoS
Genet 2013;9:e1003557.
37. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW.
The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/
ACTR/TRAM-1) is required for normal growth, puberty, female
reproductive function, and mammary gland development.
Proc Natl Acad Sci USA 2000;97:6379e84.
A. Tsezou / Osteoarthritis and Cartilage 22 (2014) 2017e2024 202338. Arimura A, vn Peer M, Schr€oder AJ, Rothman PB. The tran-
scriptional co-activator p/CIP (NCoA-3) is up-regulated by
STAT6 and serves as a positive regulator of transcriptional
activation by STAT6. J Biol Chem 2004;279:31105e12.
39. Nicholls JJ, Brassill MJ, Williams GR, Bassett JH. The skeletal
consequencesof thyrotoxicosis. J Endocrinol 2012;213:209e21.
40. Rushton MD, Gee FH, Reynard LN, Loughlin J. The osteoar-
thritis association marked by SNP rs6094710 mediates its ef-
fects by reducing the expression of NCOA3 in joint tissues.
Osteoarthritis and Cartilage 2014;22:S237.
41. Simopoulou T, Malizos KN, Iliopoulos D, Stefanou N,
Papatheodorou L, Ioannou M, et al. Differential expression of
leptin and leptin's receptor isoform (Ob-Rb) mRNA between
advanced and minimally affected osteoarthritic cartilage; ef-
fect on cartilage metabolism. Osteoarthritis and Cartilage
2007;15:872e83.
42. Xu Y, Barter MJ, Swan DC, Rankin KS, Rowan AD, Santibanez-
Koref M, et al. Identiﬁcation of the pathogenic pathways in
osteoarthritic hip cartilage: commonality and discord between
hip and knee OA. Osteoarthritis and Cartilage 2012;20:
1029e38.
43. Gelse K, Ekici AB, Cipa F, Swoboda B, Carl HD, Olk A, et al.
Molecular differentiation between osteophytic and articular
cartilageeclues for a transient and permanent chondrocyte
phenotype. Osteoarthritis and Cartilage 2012;20:162e71.
44. Lambert C, Dubuc JE, Montell E, Verges J, Munaut C, No€el A,
et al. Gene expression pattern of synovial cells from inﬂam-
matory and normal areas of osteoarthritis synovial membrane.
Arthritis Rheum 2013;66:960e8.
45. Schelbergen RF, de Munter W, van den Bosch MH, Lafeber FP,
Vogl T, Roth J, et al. Alarmins S100A8/S100A9 stimulate
osteophyte formation in experimental osteoarthritis and pre-
dict osteophyte progression in the check cohort of early hu-
man osteoarthritis patients. Osteoarthritis and Cartilage
2014;22:S303.
46. RemstDF, BlomAB,Vitters EL, BankRA, vandenBergWB,Blaney
Davidson EN, et al. Gene expression analysis of murine and
human osteoarthritis synovium reveals elevation of trans-
forming growth factor beta-responsive genes in osteoarthritis-
related ﬁbrosis. Arthritis Rheumatol 2014;66:647e56.
47. Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, Chang JH, et al.
Genome-wide expression proﬁles of subchondral bone in
osteoarthritis. Arthritis Res Ther 2013;15:R190.
48. Ramos YF, Bos SD, Lakenberg N, B€ohringer S, den
Hollander WJ, Kloppenburg M, et al. Genes expressed in blood
link osteoarthritis with apoptotic pathways. Ann Rheum Dis
2013; Jul 17, http://dx.doi.org/10.1136/annrheumdis-2013-
203405. [Epub ahead of print].
49. Oppermann U. Why is epigenetics important in understanding
the pathogenesis of inﬂammatory musculoskeletal diseases?
Arthritis Res Ther 2013;15:209.
50. Delgado-Calle J, Fernandez AF, Sainz J, Zarrabeitia MT,
Sa~nudo C, García-Renedo R, et al. Genome-wide proﬁling of
bone reveals differentially methylated regions in osteoporosis
and osteoarthritis. Arthritis Rheum 2013;65:197e205.
51. Cheung KS, Hashimoto K, Yamada N, Roach HI. Expression of
ADAMTS-4 by chondrocytes in the surface zone of human
osteoarthritic cartilage is regulated by epigenetic DNA de-
methylation. Rheumatol Int 2009;29:525e34.
52. da Silva MA, Yamada N, Clarke NM, Roach HI. Cellular and
epigenetic features of a young healthy and a young osteoar-
thritic cartilage compared with aged control and OA cartilage.
J Orthop Res 2009;27:593e601.
53. Roach HI, Yamada N, Cheung KS, Tilley S, Clarke NM, Oreffo RO,
et al. Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and
demethylation of speciﬁc CpG sites in the promoter regions.
Arthritis Rheum 2005;52:3110e24.
54. Bui C, Barter MJ, Scott JL, Xu Y, Galler M, Reynard LN, et al.
cAMP response element-binding (CREB) recruitment following
a speciﬁc CpG demethylation leads to the elevated expression
of the matrix metalloproteinase 13 in human articular chon-
drocytes and osteoarthritis. FASEB J 2012;26:3000e11.
55. de Andres MC, Imagawa K, Hashimoto K, Gonzalez A, Roach HI,
Goldring MB, et al. Loss of methylation in CpG sites in the NF-
kappaB enhancer elements of inducible nitric oxide synthase is
responsible for gene induction in human articular chon-
drocytes. Arthritis Rheum 2013;65:732e42.
56. Hashimoto K, Otero M, Imagawa K, de Andres MC, Coico JM,
Roach HI, et al. Regulated transcription of human matrix
metalloproteinase 13 (MMP13) and interleukin-1beta (IL1B)
genes in chondrocytes depends on methylation of speciﬁc
proximal promoter CpG sites. J Biol Chem 2013;288:
10061e72.
57. Scott JL, Gabrielides C, Davidson RK, Swingler TE, Clark IM,
Wallis GA, et al. Superoxide dismutase downregulation in
osteoarthritis progression and end-stage disease. Ann Rheum
Dis 2010;69:1502e10.
58. Fernandez-Tajes J, Soto-Hermida A, Vazquez-Mosquera ME,
Cortes-Pereira E, Mosquera A, Fernandez-Moreno M, et al.
Genome-wide DNA methylation analysis of articular chon-
drocytes reveals a cluster of osteoarthritic patients. Ann
Rheum Dis 2014;73:668e77.
59. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet
proteins can convert 5-methylcytosine to 5-formylcytosine
and 5-carboxylcytosine. Science 2011;333:1300e3.
60. Taylor SE, Smeriglio P, Dhulipala L, Rath M, Bhutani N. A global
increase in 5-hydroxymethylcytosine levels marks osteoar-
thritic chondrocytes. Arthritis Rheum 2014;66:90e100.
61. den Hollander W, Ramos YF, Bos SD, Bomer N, van der
Breggen R, Lakenberg N, et al. Genome wide DNA methylation
proﬁling of osteoarthritic articular cartilage. Osteoarthritis and
Cartilage 2014;22:S40e1.
62. Rushton MD, Reynard LN, Barter MJ, Rankin KS, Young DA,
Loughlin J. Characterisation of the cartilage DNA methylome in
knee and hip osteoarthritis using high-density genome-wide
analysis. Osteoarthritis and Cartilage 2014;22:S233.
63. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and
function. Cell 2004;116:281e97.
64. Iliopoulos D, Malizos KN, Oikonomou P, Tsezou A. Integrative
microRNA and proteomic approaches identify novel osteoar-
thritis genes and their collaborative metabolic and inﬂam-
matory networks. PLoS One 2008;3:e3740.
65. Jones SW, Watkins G, Le Good N, Roberts S, Murphy CL,
Brockbank SM, et al. The identiﬁcation of differentially
expressed microRNA in osteoarthritic tissue that modulate the
production of TNF-alpha and MMP13. Osteoarthritis and
Cartilage 2009;17:464e72.
66. Díaz-Prado S, Cicione C, Mui~nos-Lopez E, Hermida-Gomez T,
Oreiro N, Fernandez-Lopez C, et al. Characterization of micro-
RNA expression proﬁles in normal and osteoarthritic human
chondrocytes. BMC Musculoskelet Disord 2012;13:144.
67. Miyaki S, Nakasa T, Otsuki S, Grogan SP, Higashiyama R,
Inoue A, et al. MicroRNA-140 is expressed in differentiated
human articular chondrocytes and modulates interleukin-1
responses. Arthritis Rheum 2009;60:2723e30.
68. Tuddenham L, Wheeler G, Ntounia-Fousara S, Waters J,
Hajihosseini MK, Clark I, et al. The cartilage speciﬁc microRNA-
140 targets histone deacetylase 4 in mouse cells. FEBS Lett
2006;580:4214e7.
A. Tsezou / Osteoarthritis and Cartilage 22 (2014) 2017e2024202469. Nakamura Y, Inloes JB, Katagiri T, Kobayashi T. Chondrocyte-
speciﬁc microRNA-140 regulates endochondral bone devel-
opment and targets Dnpep to modulate bone morphogenetic
protein signaling. Mol Cell Biol 2011;31:3019e28.
70. Liang ZJ, Zhuang H, Wang GX, Li Z, Zhang HT, Yu TQ, et al.
MiRNA-140 is a negative feedback regulator of MMP-13 in IL-
1beta-stimulated human articular chondrocyte C28/I2 cells.
Inﬂamm Res 2012;61:503e9.
71. Akhtar N, Rasheed Z, Ramamurthy S, Anbazhagan AN, Voss FR,
Haqqi TM. MicroRNA-27b regulates the expression of matrix
metalloproteinase 13 in human osteoarthritis chondrocytes.
Arthritis Rheum 2010;62:1361e71.
72. Tardif G, Hum D, Pelletier JP, Duval N, Martel-Pelletier J.
Regulation of the IGFBP-5 and MMP-13 genes by the micro-
RNAs miR-140 and miR-27a in human osteoarthritic chon-
drocytes. BMC Musculoskelet Disord 2009;10:148.
73. Li J, Huang J, Dai L, Yu D, Chen Q, Zhang X, et al. miR-146a, an
IL-1beta responsive miRNA, induces vascular endothelial
growth factor and chondrocyte apoptosis by targeting Smad4.
Arthritis Res Ther 2012;14:R75.
74. Yamasaki K, Nakasa T, Miyaki S, Ishikawa M, Deie M, Adachi N,
et al. Expression of MicroRNA-146a in osteoarthritis cartilage.
Arthritis Rheum 2009;60:1035e41.
75. Wang JH, Shih KS, Wu YW, Wang AW, Yang CR. Histone
deacetylase inhibitors increase microRNA-146a expression
and enhance negative regulation of interleukin-1beta
signaling in osteoarthritis ﬁbroblast-like synoviocytes. Osteo-
arthritis and Cartilage 2013;21:1987e96.76. Matsukawa T, Sakai T, Yonezawa T, Hiraiwa H, Hamada T,
Nakashima M, et al. MicroRNA-125b regulates the expression
of aggrecanase-1 (ADAMTS-4) in human osteoarthritic chon-
drocytes. Arthritis Res Ther 2013;15:R28.
77. Park SJ, Cheon EJ, Kim HA. MicroRNA-558 regulates the
expression of cyclooxygenase-2 and IL-1b-induced catabolic
effects in human articular chondrocytes. Osteoarthritis and
Cartilage 2013;21:981e9.
78. Park SJ, Cheon EJ, Lee MH, Kim HA. MicroRNA-127-5p regu-
lates matrix metalloproteinase 13 expression and interleukin-
1beta-induced catabolic effects in human chondrocytes.
Arthritis Rheum 2013;65:3141e52.
79. Vonk LA, Kragten AH, Dhert WJ, Saris DB, Creemers LB. Over-
expression of hsa-miR-148a promotes cartilage production
and inhibits cartilage degradation by osteoarthritic chon-
drocytes. Osteoarthritis and Cartilage 2014;22:145e53.
80. Zhang Y, Jia J, Yang S, Liu X, Ye S, Tian H. MicroRNA-21 controls
the development of osteoarthritis by targeting GDF-5 in
chondrocytes. Exp Mol Med 2014;46:e79.
81. Le L, Swingler TE, Crowe N, Driscoll C, Vincent TL, Barter MJ,
et al. The microRNA-29 family in osteoarthritis. Osteoarthritis
and Cartilage 2014;22:S41e2.
82. Beyer C, Zampetaki A, Lin NY, Kleyer A, Perricone C,
Iagnocco A, et al. Signature of circulating microRNAs in oste-
oarthritis. Ann Rheum Dis 2014; Feb 27, http://dx.doi.org/
10.1136/annrheumdis-2013-204698. [Epub ahead of print].
